Acute myeloid leukemia

Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Bernard J, Boiron M, Jacquillat C, Weil M, Najean Y. Un nouvel agent actif dans le traitement des leucémies aiguës: la cytosine arabinoside. Presse Med. 1966;74:799–802.

    CAS  PubMed  Google Scholar 

  2. 2.

    Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood. 1968;32:507–23.

    CAS  Article  Google Scholar 

  3. 3.

    Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009;10:1657–74.

    CAS  Article  Google Scholar 

  4. 4.

    Abraham A, Varatharajan S, Karathedath S, Philip C, Lakshmi KM, Jayavelu AK, et al. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Pharmacogenomics. 2015;16:877–90.

    CAS  Article  Google Scholar 

  5. 5.

    Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57:485–8.

    CAS  PubMed  Google Scholar 

  6. 6.

    Coltman CA Jr, Bodey GP, Hewlett JS, Haut A, Bickers J, Balcerzak SP, et al. Chemotherapy of acute leukemia: a comparison of vincristine, cytarabine, and prednisone alone and in combination with cyclophosphamide or daunorubicin. Arch Intern Med. 1978;138:1342–8.

    Article  Google Scholar 

  7. 7.

    Ho DH, Frei E 3rd. Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Clin Pharm Ther. 1971;12:944–54.

    CAS  Article  Google Scholar 

  8. 8.

    Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer. 1979;44:1189–93.

    CAS  Article  Google Scholar 

  9. 9.

    Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, et al. Saturation of 1-beta-D-arabinofuranosylcytosine 5’-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res. 1987;47:3005–11.

    CAS  PubMed  Google Scholar 

  10. 10.

    Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood. 2013;121:26–28.

    Article  Google Scholar 

  11. 11.

    Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896–903.

    CAS  Article  Google Scholar 

  12. 12.

    Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173–9.

    CAS  PubMed  Google Scholar 

  13. 13.

    Magina KN, Pregartner G, Zebisch A, Wölfler A, Neumeister P, Greinix HT, et al. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood. 2017;130:946–8.

    CAS  Article  Google Scholar 

  14. 14.

    Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, et al. Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J. 2017;7:e564.

    CAS  Article  Google Scholar 

  15. 15.

    Dumas PY, Bertoli S, Bérard E, Leguay T, Tavitian S, Galtier J, et al. Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. Blood Adv. 2020;4:3840–9.

    Article  Google Scholar 

  16. 16.

    Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88:2841–51.

    CAS  Article  Google Scholar 

  17. 17.

    Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710–7.

    CAS  Article  Google Scholar 

  18. 18.

    Garcia-Manero G, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, et al. SWOG S1203: a randomized phase III study of standard cytarabine plus daunorubicin (7+3) therapy versus idarubicin with high dose cytarabine (IA) with or without vorinostat (IA+V) in younger patients with previously untreated acute myeloid leukemia (AML) [abstract]. Blood. 2016;128:901.

    Article  Google Scholar 

  19. 19.

    Wei H, Wang Y, Gale RP, Lin D, Zhou C, Liu B, et al. Randomized trial of intermediate-dose cytarabine in induction and consolidation therapy in adults with acute myeloid leukemia. Clin Cancer Res. 2020;26:3154–61.

    CAS  Article  Google Scholar 

  20. 20.

    Röllig C, Kramer M, Gabrecht M, Hänel M, Herbst R, Kaiser U, et al. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. Ann Oncol. 2018;29:973–8.

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Roland B. Walter.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Walter, R.B., Appelbaum, F.R. & Estey, E.H. Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia. Leukemia (2020).

Download citation


Quick links